2024 was pivotal for UK Life Sciences’ venture funding landscape. Softening macro and geopolitical conditions saw activity ...

I’ve got my eye on four trends – the maturation of AI-powered drug development, fierce competition in the GLP-1 space, the ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

In Part 7 – the final instalment of our inaugural Life Sciences Industry Report – we look more closely at reporting from 2024 ...

Pharma trade organisations in the US have told President Trump that tariffs such as the 10% levy on Chinese imports could drive up the cost of generic medicines, impact supply chains, and exacerbate ...

There was a standoff between USAID and Elon Musk's Department of Government Efficiency (DOGE) over access to restricted areas ...

That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...